申请人:ChemoCentryx, Inc.
公开号:US20140121195A1
公开(公告)日:2014-05-01
Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
提供了结合CCR(4)的苯并咪唑、苯并吡唑和苯并三唑化合物,可用于治疗过敏性疾病、自身免疫疾病、移植排斥和癌症等疾病。